Comparative Pharmacology
Head-to-head clinical analysis: LOXITANE C versus MOLINDONE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOXITANE C versus MOLINDONE HYDROCHLORIDE.
LOXITANE C vs MOLINDONE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loxapine, a dibenzoxazepine antipsychotic, acts primarily by blocking dopamine D2 receptors in the brain. It also exhibits affinity for serotonin 5-HT2A receptors, alpha-adrenergic, histaminergic, and muscarinic receptors, contributing to its antipsychotic and sedative effects.
Dopamine D2 receptor antagonist; also blocks serotonin 5-HT2A receptors and alpha-adrenergic receptors.
10 mg orally twice daily initially; may increase by 10 mg/day every 3–4 days; usual therapeutic range 60–100 mg/day; maximum 250 mg/day.
50-225 mg/day orally in 3-4 divided doses; usual effective dose 50-75 mg/day; maximum 225 mg/day.
None Documented
None Documented
Terminal elimination half-life is 4-8 hours (mean 6 hours). Clinical context: Requires multiple daily dosing; stable plasma levels achieved by second day.
1.5-2 hours; shorter than typical antipsychotics, requiring multiple daily dosing.
Approximately 70% renal (mainly as conjugated metabolites, <1% unchanged), 30% fecal via biliary excretion.
Renal: 65-70% as metabolites and unchanged drug; Fecal: 20-25%; Biliary: minor.
Category C
Category C
Antipsychotic
Antipsychotic